iBet uBet web content aggregator. Adding the entire web to your favor.
iBet uBet web content aggregator. Adding the entire web to your favor.



Link to original content: https://pubmed.ncbi.nlm.nih.gov/28073583/
Clinical factors associated with subclinical spread of in situ melanoma - PubMed Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Apr;76(4):707-713.
doi: 10.1016/j.jaad.2016.10.049. Epub 2017 Jan 7.

Clinical factors associated with subclinical spread of in situ melanoma

Thuzar M Shin  1 , Jeremy R Etzkorn  2 , Joseph F Sobanko  2 , David J Margolis  2 , Joel M Gelfand  2 , Emily Y Chu  2 , Rosalie Elenitsas  2 , Waqas R Shaikh  2 , Christopher J Miller  2
Affiliations

Clinical factors associated with subclinical spread of in situ melanoma

Thuzar M Shin et al. J Am Acad Dermatol. 2017 Apr.

Abstract

Background: Subclinical spread of in situ melanoma occurs at a wide frequency, ranging from 12% to 71%.

Objective: To identify clinical factors associated with subclinical spread of in situ melanoma.

Methods: We used a retrospective, cross-sectional study of 674 consecutive in situ melanomas to examine 627 patients treated with Mohs surgery and melanoma antigen recognized by T cells 1 immunostaining. The presence of subclinical spread was correlated with clinical characteristics. Univariate and multivariate logistic regression analyses were performed to generate odds ratios (ORs) and 95% confidence intervals (CIs).

Results: Both univariate and multivariate analyses demonstrated significantly increased odds for subclinical spread of in situ melanomas when they were located on the head or neck, at acral sites, or on the pretibial leg (OR 1.97, 95% CI 1.41-3.40); in persons with a history of prior treatment (OR 2.77, 95% CI 1.74-4.420); melanomas of preoperative size >1 cm (OR 1.74, 95% CI 1.23-2.46, P = .002); or in persons ≥60 years old (OR 1.47, 95% CI 1.01-2.13, P = .042). A count prediction model demonstrated that the risk for subclinical spread increased with the number of clinical risk factors.

Limitation: We used a single-site, retrospective study design.

Conclusion: Clarifying the risk factors for subclinical spread might help to refine triage of in situ melanomas to the appropriate surgical techniques for margin assessment prior to reconstruction.

Keywords: Mohs micrographic surgery; appropriate use criteria; excision; lentigo maligna; melanoma in situ; subclinical spread.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

MeSH terms